Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Common Equity (2016 - 2025)

Historic Common Equity for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $13.5 million.

  • Editas Medicine's Common Equity fell 9234.03% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 9234.03%. This contributed to the annual value of $134.3 million for FY2024, which is 6153.68% down from last year.
  • As of Q3 2025, Editas Medicine's Common Equity stood at $13.5 million, which was down 9234.03% from $19.2 million recorded in Q2 2025.
  • Editas Medicine's 5-year Common Equity high stood at $638.0 million for Q1 2021, and its period low was $13.5 million during Q3 2025.
  • Moreover, its 5-year median value for Common Equity was $360.5 million (2023), whereas its average is $342.3 million.
  • As far as peak fluctuations go, Editas Medicine's Common Equity soared by 17198.88% in 2021, and later crashed by 9234.03% in 2025.
  • Editas Medicine's Common Equity (Quarter) stood at $553.6 million in 2021, then plummeted by 34.85% to $360.7 million in 2022, then dropped by 3.21% to $349.1 million in 2023, then plummeted by 61.54% to $134.3 million in 2024, then plummeted by 89.98% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q3 2025, $19.2 million for Q2 2025, and $62.4 million during Q1 2025.